Thin Filament Fluorescence Assay for Calcium Dissociation Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods focus solely on troponin to examine thin filament relaxation, lacking a comprehensive system to detect small molecules that modulate thin filament dynamics, particularly in cardiac muscle function, which is crucial for treating conditions like hypertrophic cardiomyopathy (HCM) due to diastolic dysfunction.
Innovation Solution
A reconstituted thin filament system comprising modified human cardiac troponin protein with fluorescent dye conjugates, specifically at A28, and optionally cysteine substitutions, along with actin and tropomyosin proteins, to detect structural changes and calcium dissociation kinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a reconstituted thin filament system with fluorescent dye conjugates is used, then measurement precision of thin filament modulation is improved, but device complexity increases
Solution Approach 1:
The patent introduces fluorescent dye conjugates (e.g., IANBD, TMR, FMAL) as intermediary probes attached to specific cysteine residues (A28, C80, C97) of cardiac troponin I. These fluorescent probes act as mediators that report structural changes in the thin filament system through fluorescence lifetime or intensity changes, enabling precise detection without directly measuring the complex protein interactions themselves.
Solution Approach 2:
The patent replaces direct mechanical or biochemical measurement of thin filament modulation with optical detection methods. By using fluorescence lifetime imaging (FLIM) or intensity-based assays, the system substitutes complex mechanical measurements with optical signals that are easier to detect and quantify with high precision.
2Measurement precision
If site-specific cysteine substitutions and fluorescent dye conjugates are introduced, then detection sensitivity is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent introduces cysteine substitutions at specific local positions (A28, C80, C97) within the cardiac troponin I protein sequence. These localized modifications are strategically placed in regions that report different aspects of thin filament conformational changes. The site-specific nature of these modifications allows precise control over which structural transitions are detected, improving overall detection sensitivity while managing manufacturing complexity through focused modification strategies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Successfully identifies small molecules that alter calcium dissociation rates from thin filaments, providing a high-throughput screening method for modulating cardiac muscle function and potentially treating HCM.
Implementation Method 1
a modified human cardiac troponin protein comprising a modification at A28 and a fluorescent dye conjugate to said modification
Implementation Method 2
TR-FRET data on the N-terminus of cardiac troponin I indicate that phosphorylation of cTnI-Ser23/24 induces significant structural changes
Data Source
AI summary
High-throughput screening (HTS) assays described herein rely on structural alterations triggered by cTnI phosphorylation during beta-adrenergic stimulation. These HTS assays may be used to pinpointsmall molecules that emulate phosphorylation effects, amplifying lusitropy by accelerating calcium dissociation from thin filaments. With a focus on addressing diastolic dysfunction, especially in conditions like HCM, the aim is to determine compounds tailored to modulate diastolic performance.